OmniAb (OABI) Long-Term Investments (2021 - 2022)
OmniAb (OABI) reported Long-Term Investments of $237.2 million for Q3 2022, up 0.61% year-over-year from $235.8 million in Q3 2021, and little changed on a QoQ basis from $236.1 million in Q2 2022.
OmniAb (OABI) has 2 years of Long-Term Investments data on file, last reported at $237.2 million in Q3 2022.
- Quarterly Long-Term Investments rose 0.61% year-over-year to $237.2 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $237.2 million (up 0.61% YoY) and the FY2021 annual result came in at $235.8 million, changed N/A from the prior year.
- Long-Term Investments steadied at $237.2 million in Q3 2022 per OABI's latest filing, from $236.1 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $237.2 million in Q3 2022 and bottomed at $235.8 million in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 237.19 Mn |
| Jun 30, 2022 | 236.10 Mn |
| Mar 31, 2022 | 235.80 Mn |
| Dec 31, 2021 | 235.75 Mn |
| Sep 30, 2021 | 235.75 Mn |